A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, boosting plans to take a second shot at FDA approval.

Enhertu has recently become one of the key drugs in AstraZeneca and Daiichi Sankyo’s arsenal. For all of 2023, AZ recorded $1.28 billion in Enhertu revenue, which mainly included its share of ...

AstraZeneca, Daiichi withdraw lung cancer approval application for Enhertu follow-up and try again Median progression-free survival (PFS) was numerically higher in the pooled analysis, 5.8 months ...

Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell lung cancer, showing significant improvement in progression-free survival ...

Daiichi Sankyo's ADCs, particularly trastuzumab deruxtecan (Enhertu) and datopotamab deruxtecan, are showing promising results in treating various cancers, including HER2-mutated NSCLC and HER2 ...

Merck and Japan-based Daiichi Sankyo have withdrawn their U.S. application for an experimental lung cancer treatment after it failed to prolong the lives of patients in a late-stage study, the ...

Enhertu is currently approved as a second-line treatment for HER2-positive metastatic breast cancer. The new results for the AstraZeneca and Daiichi Sankyo drug in the first-line setting are ...

Daiichi Sankyo said on Friday it would invest about 1 billion euros ($1.07 billion) to expand a site near Munich, Germany, to boost its work on precision cancer drugs. Future of Health category ...

Daiichi Sankyo (DSNKY) and AstraZeneca’s (AZN) Enhertu has been approved in the European Union as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone ...